SOPHiA GENETICS
Cloud native genomics analysis company (NASDAQ: SOPH). The SOPHiA DDM platform applies machine learning with patented algorithms to call, annotate, and pre classify variants from next generation sequencing data, technology agnostic across sequencing instruments, with genomics, radiomics, and multimodal analytics modules. Deployed as software that hospitals and labs run themselves: at Mount Sinai, for example, SOPHiA provides the analytical software while the health system runs it as a laboratory developed test in its own CLIA certified, CAP accredited lab. The platform reports a network of more than 750 hospitals, academic centers, and labs and a federated learning model across participating institutions. Certain applications are research use only and regional clearance varies.
Capability Axes
The product is the AI: SOPHiA DDM uses machine learning with patented algorithms to call, annotate, and pre classify genomic variants from raw sequencing data, distinguishing clinically relevant alterations from sequencing noise. Analysis is the deliverable.
Scale is well documented (reported 1.8 million plus genomic profiles analyzed, roughly 30,000 analyses per month, 750+ institutions). Analytical validation studies exist including a clinical trial assay validation with a research partner; independent performance figures per application were not compiled this pass.
Positioning is stated with appropriate care: the platform is IVDR certified for certain applications in the EU, while some applications are labeled Research Use Only and clearance varies by country. Deployments such as Mount Sinai run DDM as a laboratory developed test in the customer's own CLIA certified, CAP accredited lab, with SOPHiA providing software and not performing diagnostic testing. Graded on clarity of regulatory positioning, not on possession of a specific US clearance.
Cloud native and decentralized by design, deployed into hospital and lab workflows across a reported 750+ institution network with a federated learning approach that keeps analysis distributed. Held back from A because specific data residency commitments by region were not retrieved.
No public pricing. Contact the vendor. Enterprise and per analysis models are referenced in third party coverage but no rate card is published.
Announced Deployments
Publicly announced health system deployments and partnerships. This is a record of announcements, not an assessment of deployment success or scale.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact the vendor
|
Enterprise and per analysis agreements for the DDM platform | — | — | Third Party Estimated |
Enterprise and per analysis models are referenced in third party coverage; SOPHiA is a public company (NASDAQ: SOPH) so aggregate economics appear in filings, but platform pricing is not published.